Importantly, cytokine release syndrome (CRS), one of the most common toxicities of CAR T cell therapy, is driven by cascades of inflammatory cytokines, including IL-6, GM-CSF, TNF, and IFNγ [53,54,55]. This evidence concerns the gene CSF2 and congenital rubella syndrome.